Zymeworks (ZYME) announced the full-time appointments of Adam Schayowitz and Scott Platshon as of April 9, from their previously interim roles. Schayowitz has been appointed as EVP and Head of Research & Development. Platshon will serve as EVP and Chief Business Officer and continue to lead Zymeworks’ asset aggregation strategy while managing expected future cash flows from Ziihera and other licensed healthcare assets, including pasritamig, which is being advanced into Phase 3 registration studies by Johnson & Johnson Innovative Medicine. Schayowitz and Platshon both join the executive leadership team from EcoR1 Capital, a shareholder in Zymeworks.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
- Zymeworks Names Kristin Stafford as New Chief Financial Officer
- Zymeworks appoints Kristin Stafford as CFO
- Zymeworks (ZYME): Advancing ADC Platform, Fast-Track ZW191, and Broad FRα Opportunity Support Buy Rating
- Zymeworks Wins FDA Fast Track Status for Ovarian Cancer Drug ZW191